PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 51,43 | 51,43 | 2024-12-23 |
| Vict Th Engwalls Stiftelse | 2,75 | 2,75 | 2024-12-23 |
| Arne Skogvall | 2,20 | 2,20 | 2024-12-23 |
| Arne Arvidsson | 1,72 | 1,72 | 2024-12-23 |
| Avanza Pension | 1,41 | 1,41 | 2024-12-23 |
| Nordnet Pensionsförsäkring | 0,77 | 0,77 | 2024-12-23 |
| Staffan Engelbert Bodén | 0,59 | 0,59 | 2024-12-23 |
| Tommy Johansson | 0,59 | 0,59 | 2024-12-23 |
| Merrick Lee Tabor | 0,45 | 0,45 | 2024-12-23 |
| Monica Billgert | 0,44 | 0,44 | 2024-12-23 |
2025-02-20 Bokslutskommuniké 2024